Gabriella Gobbi

Last updated

Gabriella Gobbi is an Italo-Canadian psychiatrist and neuroscientist whose research explores novel treatments for mental health disorders. [1] [2] [3] Gobbi is a professor at McGill University's Department of Psychiatry and a Canada Research Chair (Tier 1) in Therapeutics for Mental Health. [2] [4]

Contents

Research career

In 1991, Gobbi completed a Doctor of Medicine degree, and specialized in Psychiatry and Psychotherapy (1995) at the Catholic University of Rome in Italy and later obtained a PhD in neuroscience under the supervision of Gianluigi Gessa. [1]

Scientific contributions

Psychedelics for anxiety

Gobbi's research has shown that regular administration of low doses of LSD (lysergic acid diethylamide) reduces anxiety, through mechanisms similar commonly prescribed classes of antidepressants and selective serotonin reuptake inhibitors (SSRIs), and that LSD signaling also activates the mTOR signalling pathway. [5] [6] [7] [8]

Cannabis and association with depression in adolescence

Dr. Gobbi's lab discovered that adolescent cannabis consumption induces depression-like behavior in animals. [9] [10] Upon finding that there is a link between depression and long-term cannabis consumption in young people, [11] Gobbi engaged widely with stakeholders and the media, ultimately resulting in a change in the legal age of cannabis consumption in Quebec from 18 to 21, and her receiving the 2020 Principal's Prize for Public Engagement through Media (Established Academics category) from McGill University. [12]

Melatonin MT2 receptor agonists for pain and insomnia

Even if melatonin was isolated more than 60 years ago, the roles of GPCR melatonin receptors (named MT1 and MT2) remained unknown. Her lab discovered that the MT1 and MT2 receptors have very specialized functions: while the MT1 activates REM sleep, the MT2 receptor acts on NREM sleep. [13] [14] Her lab also synthesized and developed novel selective MT2 receptors partial agonists for the treatment of insomnia [15] and neuropathic pain. [16]

Honors and awards

Dr Gobbi is a fellow of the American College of Neuropsychopharmacology and President-elect of the International College of Neuropsychopharmacology [17]

Selected academic publications

Related Research Articles

<span class="mw-page-title-main">LSD</span> Hallucinogenic drug

Lysergic acid diethylamide, commonly known as LSD, and known colloquially as acid or lucy, is a potent psychedelic drug. Effects typically include intensified thoughts, emotions, and sensory perception. At sufficiently high dosages, LSD manifests primarily mental, visual, and auditory hallucinations. Dilated pupils, increased blood pressure, and increased body temperature are typical.

<span class="mw-page-title-main">Psychopharmacology</span> Study of the effects of psychoactive drugs

Psychopharmacology is the scientific study of the effects drugs have on mood, sensation, thinking, behavior, judgment and evaluation, and memory. It is distinguished from neuropsychopharmacology, which emphasizes the correlation between drug-induced changes in the functioning of cells in the nervous system and changes in consciousness and behavior.

<span class="mw-page-title-main">Psychedelic drug</span> Hallucinogenic class of psychoactive drug

Psychedelics are a subclass of hallucinogenic drugs whose primary effect is to trigger non-ordinary mental states and a perceived "expansion of consciousness". Also referred to as classic hallucinogens or serotonergic hallucinogens, the term psychedelic is sometimes used more broadly to include various types of hallucinogens, such as those which are atypical or adjacent to psychedelia like salvia and MDMA, respectively.

<span class="mw-page-title-main">Ergine</span> Chemical compound

Ergine, also known as d-lysergic acid amide (LSA) and d-lysergamide, is an ergoline alkaloid that occurs in various species of vines of the Convolvulaceae and some species of fungi. The psychedelic properties in the seeds of ololiuhqui, Hawaiian baby woodrose and morning glories have been linked to ergine and/or isoergine, its epimer, as it is an alkaloid present in the seeds.

<span class="mw-page-title-main">Ergoline</span> Chemical compound

Ergoline is a chemical compound whose structural skeleton is contained in a variety of alkaloids, referred to as ergoline derivatives or ergoline alkaloids. Ergoline alkaloids, one being ergine, were initially characterized in ergot. Some of these are implicated in the condition ergotism, which can take a convulsive form or a gangrenous form. Even so, many ergoline alkaloids have been found to be clinically useful. Annual world production of ergot alkaloids has been estimated at 5,000–8,000 kg of all ergopeptines and 10,000–15,000 kg of lysergic acid, used primarily in the manufacture of semi-synthetic derivatives.

<span class="mw-page-title-main">Psilocin</span> Chemical compound

Psilocin, also known as 4-hydroxy-N,N-dimethyltryptamine (4-OH-DMT), is a substituted tryptamine alkaloid and a serotonergic psychedelic. It is present in most psychedelic mushrooms together with its phosphorylated counterpart psilocybin. Psilocin is a Schedule I drug under the Convention on Psychotropic Substances. Acting on the serotonin 5-HT2A receptors, psilocin's psychedelic effects are directly correlated with the drug's occupancy at these receptor sites. The subjective mind-altering effects of psilocin are highly variable and are said to resemble those of lysergic acid diethylamide (LSD) and N,N-dimethyltryptamine (DMT).

<span class="mw-page-title-main">Hallucinogen persisting perception disorder</span> Medical condition

Hallucinogen persisting perception disorder (HPPD) is a non-psychotic disorder in which a person experiences apparent lasting or persistent visual hallucinations or perceptual distortions after using drugs, including but not limited to psychedelics, dissociatives, entactogens, tetrahydrocannabinol (THC), and SSRIs. Despite being designated as a hallucinogen-specific disorder, the specific contributory role of psychedelic drugs is unknown.

Neuropsychopharmacology, an interdisciplinary science related to psychopharmacology and fundamental neuroscience, is the study of the neural mechanisms that drugs act upon to influence behavior. It entails research of mechanisms of neuropathology, pharmacodynamics, psychiatric illness, and states of consciousness. These studies are instigated at the detailed level involving neurotransmission/receptor activity, bio-chemical processes, and neural circuitry. Neuropsychopharmacology supersedes psychopharmacology in the areas of "how" and "why", and additionally addresses other issues of brain function. Accordingly, the clinical aspect of the field includes psychiatric (psychoactive) as well as neurologic (non-psychoactive) pharmacology-based treatments. Developments in neuropsychopharmacology may directly impact the studies of anxiety disorders, affective disorders, psychotic disorders, degenerative disorders, eating behavior, and sleep behavior.

<span class="mw-page-title-main">Ramelteon</span> Hypnotic medication

Ramelteon, sold under the brand name Rozerem among others, is a melatonin agonist medication which is used in the treatment of insomnia. It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset. It reduces the time taken to fall asleep, but the degree of clinical benefit is small. The medication is approved for long-term use. Ramelteon is taken by mouth.

Melatonin receptors are G protein-coupled receptors (GPCR) which bind melatonin. Three types of melatonin receptors have been cloned. The MT1 (or Mel1A or MTNR1A) and MT2 (or Mel1B or MTNR1B) receptor subtypes are present in humans and other mammals, while an additional melatonin receptor subtype MT3 (or Mel1C or MTNR1C) has been identified in amphibia and birds. The receptors are crucial in the signal cascade of melatonin. In the field of chronobiology, melatonin has been found to be a key player in the synchrony of biological clocks. Melatonin secretion by the pineal gland has circadian rhythmicity regulated by the suprachiasmatic nucleus (SCN) found in the brain. The SCN functions as the timing regulator for melatonin; melatonin then follows a feedback loop to decrease SCN neuronal firing. The receptors MT1 and MT2 control this process. Melatonin receptors are found throughout the body in places such as the brain, the retina of the eye, the cardiovascular system, the liver and gallbladder, the colon, the skin, the kidneys, and many others. In 2019, X-ray crystal and cryo-EM structures of MT1 and MT2 were reported.

<span class="mw-page-title-main">Effect of psychoactive drugs on animals</span>

Psychoactive drugs, such as caffeine, amphetamine, mescaline, lysergic acid diethylamide (LSD), cannabis, chloral hydrate, theophylline, IBMX and others, can have strong effects on certain animals. It is believed that plants developed caffeine as a chemical defense against insects.

<span class="mw-page-title-main">25B-NBOMe</span> Chemical compound

25B-NBOMe is a derivative of the phenethylamine psychedelic 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent full agonist for the 5HT2A receptor. Duration of effects lasts about 3–10 hours, although the parent compound is rapidly cleared from the blood when used in the radiolabeled form in tracer doses. Recently, Custodio et al. (2019) evaluated the potential involvement of dysregulated dopaminergic system, neuroadaptation, and brain wave changes which may contribute to the rewarding and reinforcing properties of 25B-NBOMe in rodents.

<span class="mw-page-title-main">25N-NBOMe</span> Chemical compound

25N-NBOMe is a derivative of the hallucinogen 2C-N. The pharmacological properties of 25N-NBOMe have not been described in the scientific literature, but it is believed to act in a similar manner to related compounds such as 25I-NBOMe and 25C-NBOMe, which are potent agonists at the 5HT2A receptor. 25N-NBOMe has been sold as a street drug and has only been described in the literature in terms of identification by forensic analysis.

<span class="mw-page-title-main">Harris Isbell</span> American pharmacologist

Harris Isbell was an American pharmacologist and the director of research for the NIMH Addiction Research Center at the Public Health Service Hospital in Lexington, Kentucky from 1945 to 1963. He did extensive research on the physical and psychological effects of various drugs on humans. Early work investigated aspects of physical dependence with opiates and barbiturates, while later work investigated psychedelic drugs, including LSD. The research was extensively reported in academic journals such as the Journal of Pharmacology and Experimental Therapeutics, Psychopharmacologia, and the AMA Archives of Neurology and Psychiatry.

<span class="mw-page-title-main">Piromelatine</span> Chemical compound

Piromelatine (Neu-P11) is a multimodal sleep drug under development by Neurim Pharmaceuticals. It is an agonist at melatonin MT1/MT2 and serotonin 5-HT1A/5-HT1D receptors. Neurim is conducting a phase II randomized, placebo controlled trial of cognitive and sleep effects in Alzheimer's disease.

<span class="mw-page-title-main">Gustavo Turecki</span> Canadian psychiatrist and academic

Gustavo Turecki is a Canadian psychiatrist, suicidologist, neuroscientist who is a professor at McGill University in Montreal, Quebec, Canada. He holds a Tier 1 Canada Research Chair Tier in Major Depressive Disorder and Suicide. He is the sitting Chair of the Department of Psychiatry at McGill University, the Scientific Director of the Douglas Research Centre, and the Psychiatrist-in-Chief of the Centre intégré universitaire de santé et de services sociaux de l’Ouest-de-l’Île-de-Montréal. He works at the Douglas Mental Health University Institute, where he heads both the McGill Group for Suicide Studies and the Depressive Disorders Program, and is the co-director of the Douglas Bell-Canada Brain Bank.

Joel Elkes was a leading medical researcher specialising in the chemistry of the brain. He qualified as a physician in London and later became a medical researcher who published the first double-blind scientific trial on chlorpromazine to treat schizophrenia. He is regarded as the father of modern neuropsychopharmacology and directed the first experimental psychiatric Uffculme Clinic in Birmingham, UK. He was responsible for the setting up of international organisations and university departments to further the investigation of the effects of psychopharmacy. He spent the latter part of his career endeavouring to bring higher levels of humanity, compassion and ethics to medical training.

<span class="mw-page-title-main">25iP-NBOMe</span> Chemical compound

25iP-NBOMe is a derivative of the phenethylamine hallucinogen 2C-iP, which acts as a highly potent agonist for the human 5-HT2A receptor.

<span class="mw-page-title-main">1V-LSD</span> Chemical compound

1V-LSD, sometimes nicknamed Valerie, is a psychotropic substance and a research chemical with psychedelic effects. 1V-LSD is an artificial derivative of natural lysergic acid, which occurs in ergot alkaloids, as well as being an analogue of LSD. 1V-LSD has been sold online until an amendment to the German NpSG was enforced in 2022 which controls 1P-LSD and now 1cP-LSD, 1V-LSD and several other lysergamides.

References

  1. 1 2 "Dr. Gabriella Gobbi's Lab: Background".
  2. 1 2 "Gabriella Gobbi".
  3. Wolfe, Lowell. "When it comes to drugs, McGill is still stuck in the past | McGill Tribune". www.mcgilltribune.com. Retrieved 2022-06-04.
  4. "Nine Canada Research Chairs awarded to McGill". McGill Reporter. 2022-06-02. Retrieved 2022-06-04.
  5. "LSD, a future antianxiety pill?". McGill University Health Centre. Retrieved 2022-06-04.
  6. De Gregorio, Danilo; Popic, Jelena; Enns, Justine P.; Inserra, Antonio; Skalecka, Agnieszka; Markopoulos, Athanasios; Posa, Luca; Lopez-Canul, Martha; Qianzi, He; Lafferty, Christopher K.; Britt, Jonathan P. (2021-02-02). "Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission". Proceedings of the National Academy of Sciences. 118 (5): e2020705118. doi: 10.1073/pnas.2020705118 . ISSN   0027-8424. PMC   7865169 . PMID   33495318.
  7. "Tripping over the potential of psychedelics for autism". Spectrum | Autism Research News. 2022-05-31. Retrieved 2022-06-04.
  8. "LSD may offer viable treatment for certain mental disorders".
  9. Bambico, Francis Rodriguez; Nguyen, Nhu-Tram; Katz, Noam; Gobbi, Gabriella (March 2010). "Chronic exposure to cannabinoids during adolescence but not during adulthood impairs emotional behaviour and monoaminergic neurotransmission". Neurobiology of Disease. 37 (3): 641–655. doi:10.1016/j.nbd.2009.11.020. ISSN   0969-9961. PMID   19969082. S2CID   44645230.
  10. De Gregorio, Danilo; Dean Conway, Joshua; Canul, Martha-Lopez; Posa, Luca; Bambico, Francis Rodriguez; Gobbi, Gabriella (2020-07-29). "Effects of Chronic Exposure to Low-Dose delta-9-Tetrahydrocannabinol in Adolescence and Adulthood on Serotonin/Norepinephrine Neurotransmission and Emotional Behavior". International Journal of Neuropsychopharmacology. 23 (11): 751–761. doi:10.1093/ijnp/pyaa058. ISSN   1461-1457. PMC   7745253 . PMID   32725198.
  11. "'Double-edged sword:' Teens' long-term cannabis use tied to higher depression risk". CBC News. 13 February 2019.
  12. "Celebrating McGill researchers who are changing the world". McGill Reporter. 2020-04-28. Retrieved 2022-06-04.
  13. Gobbi, Gabriella; Comai, Stefano (2019-03-01). "Differential Function of Melatonin MT1 and MT2 Receptors in REM and NREM Sleep". Frontiers in Endocrinology. 10: 87. doi: 10.3389/fendo.2019.00087 . ISSN   1664-2392. PMC   6407453 . PMID   30881340.
  14. Comai, Stefano; Ochoa-Sanchez, Rafael; Gobbi, Gabriella (April 2013). "Sleep–wake characterization of double MT1/MT2 receptor knockout mice and comparison with MT1 and MT2 receptor knockout mice". Behavioural Brain Research. 243: 231–238. doi:10.1016/j.bbr.2013.01.008. ISSN   0166-4328. PMID   23333399. S2CID   7363091.
  15. Ochoa-Sanchez, R.; Comai, S.; Lacoste, B.; Bambico, F. R.; Dominguez-Lopez, S.; Spadoni, G.; Rivara, S.; Bedini, A.; Angeloni, D.; Fraschini, F.; Mor, M.; Tarzia, G.; Descarries, L.; Gobbi, G. (2011-12-14). "Promotion of Non-Rapid Eye Movement Sleep and Activation of Reticular Thalamic Neurons by a Novel MT2 Melatonin Receptor Ligand". Journal of Neuroscience. 31 (50): 18439–18452. doi:10.1523/jneurosci.2676-11.2011. ISSN   0270-6474. PMC   6623882 . PMID   22171046.
  16. Lopez-Canul, Martha; Palazzo, Enza; Dominguez-Lopez, Sergio; Luongo, Livio; Lacoste, Baptiste; Comai, Stefano; Angeloni, Debora; Fraschini, Franco; Boccella, Serena; Spadoni, Gilberto; Bedini, Annalida; Tarzia, Giorgio; Maione, Sabatino; Granados-Soto, Vinicio; Gobbi, Gabriella (February 2015). "Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways". Pain. 156 (2): 305–317. doi:10.1097/01.j.pain.0000460311.71572.5f. hdl: 11576/2623398 . ISSN   0304-3959. PMID   25599452. S2CID   25927444.
  17. "CINP Home". cinp.org. Retrieved 2024-09-05.
  18. Association, Canadian Medical (2022-05-17). "Canadian College of Neuropsychopharmacology 2022 award winners". Journal of Psychiatry and Neuroscience. 47 (3): E196. doi:10.1503/jpn.220082. ISSN   1180-4882. PMC   9188797 . PMID   35580895.
  19. "Gabriella Gobbi honoured by the International College of Neuropsychopharmacology". Health e-News. 2022-09-22. Retrieved 2023-01-20.
  20. "Congratulations to Dr. Gabriella Gobbi, recipient of the Principal's Prize for Public Engagement through Media". Channels. Retrieved 2023-01-20.
  21. Dr. Gabriella Gobbi, 2017 Recipient of the Dr. Samarthji Lal Award , retrieved 2023-01-20
  22. "Premio Venezia - ICCC". ICCC. Retrieved 2023-01-20.
  23. "5 TORRI - Ottobre 2013 by Comune di Osimo - Issuu". issuu.com. Retrieved 2023-01-20.
  24. 1 2 3 4 5 "Biographical Sketch". Neurobiological Psychiatry Unit. Retrieved 2023-01-20.